| Rohan Bhalla, MD | |
|
12605 E 16th Ave, Aurora, CO 80045-2545 | |
| (720) 848-0000 | |
| Not Available |
| Full Name | Rohan Bhalla |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316437593 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 0070479 (Colorado) | Primary |
| Entity Name | Denver Health And Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.
› Verified 5 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rohan Bhalla, MD Po Box 110429, Aurora, CO 80042-0429 Ph: () - | Rohan Bhalla, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The arthritis drug Vioxx could have caused an estimated 88 000–140 000 excess cases of serious coronary heart disease in the USA since its launch in 1999, concludes a study published online by The Lancet.
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.
› Verified 5 days ago
Dr. Janine L Oliver, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-1800 | |
Dr. Michael Anthony Avallone, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Brian Flynn, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Granville L Lloyd, MD Urology Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, University Of Colorado Hospital, Aurora, CO 80045 Phone: 720-848-0000 | |
Vijaya Vemulakonda, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Brian Thomas Caldwell, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 13123 E 16th Ave, Box 463, Aurora, CO 80045 Phone: 720-777-1234 | |
Eric Christian Ballon-landa, MD Urology Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |